ImmuPharma (LON:IMM) Issues Quarterly Earnings Results

ImmuPharma (LON:IMM) posted its quarterly earnings results on Wednesday. The company reported GBX (0.37) earnings per share (EPS) for the quarter, Digital Look Earnings reports. ImmuPharma had a negative return on equity of 6,634.51% and a net margin of 3,519.56%.

ImmuPharma Stock Up 6.9%

LON IMM opened at GBX 4.60 on Thursday. The stock has a market capitalization of £28.70 million, a P/E ratio of -5.17 and a beta of 2.98. ImmuPharma has a 52-week low of GBX 1.39 and a 52-week high of GBX 19.40. The firm has a 50-day moving average price of GBX 4.57 and a 200 day moving average price of GBX 6.27.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.